BeiGene announces FDA approval of Tevimbra

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Dec 27 2024

0mins

FDA Approval for Tevimbra: BeiGene, soon to be renamed BeOne Medicines, received FDA approval for Tevimbra in combination with chemotherapy for treating unresectable or metastatic HER2-negative gastric cancer in adults expressing PD-L1.
Monotherapy Approval and Additional Application: Tevimbra is also approved as a standalone treatment for metastatic esophageal squamous cell carcinoma after prior chemotherapy, with an additional application under review for first-line treatment of advanced ESCC.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.